NGL FINECHEM
|
The Current P/E Ratio of NGL FINECHEM is 38.96.
| Share Price | ₹2,205.6 | Mar 17,2026 |
| Market Cap | ₹1,367.4 Cr | |
| Earnings-TTM | ₹35.1 Cr | TTM-Consolidated Results |
| Price/Earnings | 38.96x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NGL FINECHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,367.4 Cr] as on Mar 17,2026
(/) Earnings [ ₹35.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 38.96x ]
Thus, for NGL FINECHEM , the investors are currently willing to pay 38.96 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NGL FINECHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NGL FINECHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of NGL FINECHEM
PE Ratio Performance Analysis for NGL FINECHEM
- NGL FINECHEM 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 28.31x.
- NGL FINECHEM 's operated at median p/e ratio of 31.37x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NGL FINECHEM 's p/e ratio peaked in Mar2023 at 36.22x.
- NGL FINECHEM 's p/e ratio hit its five-year low in Mar2021 of 16.74x.
How does NGL FINECHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NGL FINECHEM | 35.10 | 38.96 | 1,367.4 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 39.16 | 430,825.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 65.16 | 161,535.0 |
| CIPLA LTD | 4,544.70 | 22.78 | 103,513.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 64.14 | 145,733.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.44 | 107,094.0 |
| MANKIND PHARMA LTD | 1,796.65 | 47.51 | 85,350.2 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.15 | 89,544.8 |
| LUPIN LTD | 4,669.18 | 22.50 | 105,040.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 21.28 | 74,772.4 |
| ABBOTT INDIA LTD | 1,524.13 | 36.90 | 56,235.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NGL FINECHEM 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.15x |
| Max industry PE | 65.16x |
| Median industry PE | 36.90x |
| Average industry PE | 36.00x |
You may also like the below Video Courses